Compare ALMU & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALMU | RLMD |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.8M | 307.3M |
| IPO Year | N/A | N/A |
| Metric | ALMU | RLMD |
|---|---|---|
| Price | $15.06 | $4.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $25.50 | $10.00 |
| AVG Volume (30 Days) | 307.7K | ★ 990.2K |
| Earning Date | 02-07-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,569,000.00 | N/A |
| Revenue This Year | $20.69 | N/A |
| Revenue Next Year | $68.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 307.21 | N/A |
| 52 Week Low | $5.69 | $0.24 |
| 52 Week High | $25.88 | $5.12 |
| Indicator | ALMU | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.58 | 58.47 |
| Support Level | $14.00 | $3.98 |
| Resistance Level | $18.42 | $4.79 |
| Average True Range (ATR) | 1.50 | 0.44 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 33.11 | 61.47 |
Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.